SRR3147748
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.380
- MITOTIC_SPINDLE+0.320
- PROTEIN_SECRETION+0.310
- E2F_TARGETS+0.270
- SPERMATOGENESIS+0.200
- UV_RESPONSE_DN+0.170
- ANDROGEN_RESPONSE+0.150
- MYC_TARGETS_V1+0.090
- TGF_BETA_SIGNALING+0.080
- FATTY_ACID_METABOLISM+0.070
Top 10 suppressed
- COAGULATION-0.370
- APICAL_SURFACE-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- HYPOXIA-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- MYC_TARGETS_V2-0.320
- IL2_STAT5_SIGNALING-0.310
- INFLAMMATORY_RESPONSE-0.310
- APICAL_JUNCTION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3288 | Med | Medulloblastoma | 0.882 |
| 2 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.866 |
| 3 | TCGA-A2-A1FW-01A-11R-A13Q-07 | — | B | 0.862 |
| 4 | R144 | — | — | 0.860 |
| 5 | SRR4195674 | — | — | 0.860 |
| 6 | MDT-AP-3311 | Med | Medulloblastoma | 0.860 |
| 7 | SRR3147744 | — | — | 0.855 |
| 8 | TCGA-AO-A1KS-01A-11R-A13Q-07 | — | B | 0.851 |
| 9 | ERR2598089 | fetal | fetal | 0.846 |
| 10 | MDT-AP-3021 | Med | Medulloblastoma | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.030 | Inavolisib | — uncovered |